Elon Musk struck a deal to buy Twitter for $44 billion. Although a somewhat unconventional character, sleeping at the Tesla headquarters and eschewing wealthy materialism, make no mistake that Musk’s successful track record in business shows how significant Twitter may become under his leadership. While no one knows for sure what will be, Casey Ross – Social Media Strategy Director at FCB Health New York – looks at some of the issues Musk has publicly called out, and their potential implications for advertisers.
Studies have concluded that chatbots have the potential in treating mental health issues and could be used as an effective tool for delivering cognitive behavioral therapy.
The first rule of rare: There are no rules. There are over 7,000 different rare diseases – each with its own symptomology, history, and clinical and political landscape. Most are virgin territory for marketers; only 5 percent have an approved treatment.
It’s clearly what’s next, but to take advantage of voice device interactions pharma will have to retune its content development and review processes.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
2018 was the year of the consumer, and there is no sign of a change any time soon.
From the latest in VR to imaginative Social Engagement approaches, here are Ben Putman’s Top Five Digital Marketing takeaways for 2017.
Med Ad News asked industry experts what they thought DTC communications might look like in five years. This is what they told us.
Social media is integrated into the daily lives of consumers, often engaging with brands for customer service support – except when it comes to pharmaceutical companies.